S$0.365 HC Surgical (1B1.SI SES) +4.29% after hours 15 Jan 2026: monitor volume
The 1B1.SI stock moved to S$0.365 in after-hours trade on 15 Jan 2026, up 4.29% from the previous close on the Singapore Exchange (SES). Volume accelerated to 30,900 shares versus an average daily volume of 32,583, marking this name as a high-volume mover in the Healthcare sector. Traders are watching near-term technical levels — day high S$0.370 and year high S$0.375 — while fundamentals show a low P/E and a dividend yield that supports income-focused investors. We outline key drivers, Meyka AI grade, and a short-term forecast to inform trading and investment decisions.
1B1.SI stock: After-hours price and volume
Price closed at S$0.365 after hours on 15 Jan 2026, a +4.29% move from the prior close of S$0.350. Intraday range was S$0.365–S$0.370 and reported volume was 30,900 shares, near the 50-day average of 32,583, indicating genuine trading interest rather than a thin-session spike.
1B1.SI stock: Fundamentals and valuation
HC Surgical Specialists Limited reports EPS S$0.05 and a trailing P/E of 7.30, placing the company below the Healthcare sector average P/E of 21.28. Market capitalisation is SGD 55,982,060.00, price-to-book is 2.68, and dividend yield (TTM) is 5.42%, supporting an income case for investors. These metrics show a compact balance sheet with low leverage: debt to equity about 0.13 and interest coverage above 150x.
1B1.SI stock: Technical snapshot for traders
Momentum indicators show a constructive bias: RSI 60.81, Stochastic %K 80.00, and ADX 33.56 suggesting a strong trend. Short-term moving averages sit at 50-day 0.3463 and 200-day 0.3236, both below the current price, a bullish alignment for momentum traders. Key short-term resistance sits near the year high S$0.375 and support near S$0.345.
1B1.SI stock: Meyka AI grade and model forecast
Meyka AI rates 1B1.SI with a score out of 100: 66.97 which translates to Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of S$0.39 and a quarterly target of S$0.37. These model-based projections are not guarantees and should be used with other research inputs.
1B1.SI stock: Catalysts and risks
Near-term catalysts include outpatient volume recovery, clinic expansions, and quarterly earnings updates; 1B1.SI has an earnings announcement noted for mid-2025 historically. Risks include outpatient demand variability, regulatory changes in Singapore healthcare, and margin pressure from rising costs. The company’s return on equity 44.13% and net margin 43.72% show operational strength but also expose stock price to swings in patient volumes.
1B1.SI stock: Trading strategy and sector context
For high-volume movers, monitor real-time liquidity and limit exposure size. Short-term traders may use the current range S$0.365–S$0.375 for intraday setups with stops under S$0.345. From a sector view, Healthcare on SES shows one-year performance of +26.18%, and 1B1.SI’s valuation is more conservative versus peers, which may attract value and dividend investors. Refer to trading volumes and order book depth before initiating positions.
Final Thoughts
Key takeaways for 1B1.SI stock: the after-hours move to S$0.365 on 15 Jan 2026 reflects renewed buyer interest with near-average volume 30,900. Valuation is modest with P/E 7.30, a dividend yield near 5.42%, low leverage, and strong margins — traits that support a conservative HOLD view. Meyka AI’s forecast model projects a monthly target of S$0.39, implying an upside of 6.85% versus the current price (S$0.365). That projection is model-based and not a guarantee. Traders should watch the next sessions for confirmation above S$0.370 or a failure that would push price toward S$0.345. For investors focused on income and value within the Singapore Healthcare sector, 1B1.SI offers a clear yield and solid profitability, but liquidity and patient-volume risk remain the primary variables to monitor. This analysis is supported by Meyka AI, an AI-powered market analysis platform that blends fundamentals, technicals, and sector context
FAQs
What drove the after-hours move in 1B1.SI stock today?
The after-hours uptick to S$0.365 was driven by higher trading volume of 30,900 shares and short-term buying pressure. Market participants cited attractive valuation—P/E 7.30—and the stock’s dividend yield near 5.42% as reasons to buy into the Healthcare name.
How does Meyka AI rate 1B1.SI and what does the grade mean?
Meyka AI rates 1B1.SI with a score out of 100: 66.97, Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. It is informational, not investment advice.
What is the short-term price forecast for 1B1.SI stock?
Meyka AI’s forecast model projects a monthly target of S$0.39 and a quarterly target of S$0.37. The monthly target implies about 6.85% upside versus the current price S$0.365. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
